Drug Type Small molecule drug |
Synonyms BRD4(Checkpoint), CK 103, CK103 + [1] |
Target |
Mechanism BET inhibitors(Bromodomain and extra terminal domain protein inhibitors), BRD4 inhibitors(Bromodomain-containing protein 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization Jubilant Therapeutics, Inc.Startup |
Inactive Organization |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |
Molecular FormulaC13H9NO |
InChIKeyFZEYVTFCMJSGMP-UHFFFAOYSA-N |
CAS Registry578-95-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | US | 02 Aug 2020 | |
Solid tumor | Phase 1 | - | 02 Aug 2020 | |
Neoplasms | IND Application | US | Jubilant Therapeutics, Inc.Startup | 15 Jun 2024 |